TGF-β1 mediates the radiation response of prostate cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 60554283X | ||
| 003 | CHVBK | ||
| 005 | 20210128100923.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00109-014-1206-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00109-014-1206-6 | ||
| 245 | 0 | 0 | |a TGF-β1 mediates the radiation response of prostate cancer |h [Elektronische Daten] |c [Chun-Te Wu, Ching-Chuan Hsieh, Tzu-Chen Yen, Wen-Cheng Chen, Miao-Fen Chen] |
| 520 | 3 | |a Radiotherapy is the main treatment modality for prostate cancer. This study investigated the role of TGF-β1 in biological sequelae and tumor regrowth following irradiation, which are critical for the clinical radiation response of prostate cancer. Human and murine prostate cancer cell lines, and corresponding hormone-refractory (HR) cells, were used to examine the radiation response by clonogenic assays in vitro and tumor growth delay in vivo. Biological changes after irradiation, including cell death and tumor regrowth, were examined by experimental manipulation of TGF-β1 signaling. The correlations among tumor radiation responses, TGF-β1 levels, and regulatory T cells (Tregs) recruitment were also evaluated using animal experiments. HR prostate cancer cells appeared more radioresistant and had higher expression of TGF-β1 compared to hormone-sensitive (HS) cells. TGF-β1 expression was positively linked to irradiation and radioresistance, as demonstrated by in vitro and in vivo experiments. Inhibition of TGF-β1 increased tumor inhibition and DNA damage after irradiation. When mice were irradiated with a sub-lethal dose, the regrowth of irradiated tumors was significantly correlated with TGF-β1 levels and Tregs accumulation in vivo. Furthermore, blocking TGF-β1 clearly attenuated Tregs accumulation and tumor regrowth following treatment. These data demonstrate that TGF-β1 is important in determining the radiation response of prostate cancer, including tumor cell killing and the tumor microenvironment. Therefore, concurrent treatment with a TGF-β1 inhibitor is a potential therapeutic strategy for increasing the radiation response of prostate cancer, particularly for more aggressive or HR cancer cells. Key message: • HR prostate cancer cells appeared more radioresistant and had higher expression of TGF-β1. • TGF-β1 was positively linked to the radiation resistance of prostate cancer. • Tumor regrowth following irradiation was significantly correlated with TGF-β1 and Tregs levels. • Blocking TGF-β1 significantly attenuated RT-induced DNA repair and Tregs. • TGF-β1 inhibitor increases the radiation response of HR cancer cells. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2014 | ||
| 690 | 7 | |a TGF-β1 |2 nationallicence | |
| 690 | 7 | |a Irradiation |2 nationallicence | |
| 690 | 7 | |a Regulatory T cells |2 nationallicence | |
| 690 | 7 | |a Prostate cancer |2 nationallicence | |
| 700 | 1 | |a Wu |D Chun-Te |u Department of Urology, Chang Gung Memorial Hospital, KeeLung, Taiwan |4 aut | |
| 700 | 1 | |a Hsieh |D Ching-Chuan |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | |
| 700 | 1 | |a Yen |D Tzu-Chen |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | |
| 700 | 1 | |a Chen |D Wen-Cheng |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | |
| 700 | 1 | |a Chen |D Miao-Fen |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | |
| 773 | 0 | |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/1(2015-01-01), 73-82 |x 0946-2716 |q 93:1<73 |1 2015 |2 93 |o 109 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00109-014-1206-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00109-014-1206-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Wu |D Chun-Te |u Department of Urology, Chang Gung Memorial Hospital, KeeLung, Taiwan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hsieh |D Ching-Chuan |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yen |D Tzu-Chen |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Chen |D Wen-Cheng |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Chen |D Miao-Fen |u College of Medicine, Chang Gung University, Taoyuan, Taiwan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/1(2015-01-01), 73-82 |x 0946-2716 |q 93:1<73 |1 2015 |2 93 |o 109 | ||